Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
October 18 2021 - 9:30AM
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)
(“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing therapies for the treatment and
prevention of addiction and related disorders, today announced that
William Stilley, Chief Executive Officer and President of Adial
Pharmaceuticals, will present at the Dawson James Securities Small
Cap Growth Conference being held on October 21, 2021 at the Wyndham
Grand Hotel in Jupiter, Florida.
Mr. Stilley will present on Thursday, October
21st at 9:45 am Eastern Time and will also be participating in
one-on-one meetings with qualified investors throughout the
conference.
The live webcast and subsequent archived
recordings for the presentation can be accessed here and on the
investor relations section of Adial’s website at
https://ir.adialpharma.com/.
About Dawson James
Securities
Dawson James Securities, Inc., a member of
FINRA/SIPC, is a full-service investment bank headquartered in Boca
Raton, FL. http://www.dawsonjames.com.
About Adial Pharmaceuticals,
Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on developing therapies for the
treatment and prevention of addiction and related disorders. The
Company’s lead investigational new drug product, AD04, is a
genetically targeted, serotonin-3 receptor antagonist, therapeutic
agent for the treatment of Alcohol Use Disorder (AUD) and is
currently being investigated in the Company’s landmark ONWARD™
pivotal Phase 3 clinical trial for the potential treatment of AUD
in subjects with certain target genotypes, which are to be
identified using the Company’s proprietary companion diagnostic
genetic test. A Phase 2b clinical trial of AD04 for the treatment
of AUD showed promising results in reducing frequency of drinking,
quantity of drinking and heavy drinking (all with statistical
significance), and no overt safety concerns (there were no
statistically significant serious adverse events reported). AD04 is
also believed to have the potential to treat other addictive
disorders such as Opioid Use Disorder, gambling, and obesity. The
Company is also developing adenosine analogs for the treatment of
pain and other disorders. Additional information is available at
www.adialpharma.com.
Contact:Crescendo Communications,
LLC David
Waldman / Natalya
Rudman Tel:
212-671-1021 Email:
adil@crescendo-ir.com SOURCE: Adial
Pharmaceuticals, Inc.
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024